COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,889 Articles (22,568 medRxiv, 8,321 bioRxiv)

Most recent first Previous |  Page 2031: Articles 20301-20310  | Next

Analysis of the Dynamics and Distribution of SARS-CoV-2 Mutations and its Possible Structural and Functional Implications
Justo Arevalo, S., Zapata Sifuentes, D., Huallpa Robles, C., Landa Bianchi, G., Castillo Chavez, A., Garavito-Salini Casas, R., Pineda Chavarria, R., Uceda-Campos, G.
10.1101/2020.11.13.381228 — Posted: 2020-11-14
A comparison of DNA/RNA extraction protocols for high-throughput sequencing of microbial communities
Shaffer, J. P., Marotz, C., Belda-Ferre, P., Martino, C., Wandro, S., Estaki, M., Salido, R. A., Carpenter, C. S., Zaramela, L. S., Minich, J. J., Bryant, M. B., Sanders, K., Fraraccio, S., Ackermann, G., Humphrey, G., Swafford, A. D., Miller-Montgomery, S., Knight, R.
10.1101/2020.11.13.370387 — Posted: 2020-11-14
A Whole Virion Vaccine for COVID-19 Produced Via a Novel Inactivation Method: Results from Animal Challenge Model Studies
Ragan, I. K., Hartson, L. M., Dutt, T. S., Obregon-Henao, A., Maison, R. M., Gordy, P., Fox, A., Karger, B. R., Cross, S. T., Kapuscinski, M. L., Cooper, S. K., Podell, B. K., Stenglein, M. D., Bowen, R. A., Henao-Tamayo, M., Goodrich, R.
10.1101/2020.11.13.381335 — Posted: 2020-11-13
Plasma irradiation efficiently inactivates the coronaviruses mouse hepatitis virus and SARS-CoV-2
Morikawa, S., Watanabe, S., Fujii, H., Tanaka, T., Arai, J., Kyuwa, S.
10.1101/2020.11.13.381319 — Posted: 2020-11-13
ILRUN downregulates ACE2 expression and blocks infection of human cells by SARS-CoV-2
Tribolet, L., Alexander, M., Brice, A., Jansen Van Vuren, P., Rootes, C., Mara, K., McDonald, M., Bruce, K., Gough, T., Shi, S., Cowled, C., Bean, A., Stewart, C. R.
10.1101/2020.11.13.381343 — Posted: 2020-11-13
Comparison of seven commercial SARS-CoV-2 rapid Point-of-Care Antigen tests
Corman, V. M., Haage, V. C., Bleicker, T., Schmidt, M. L., Muehlemann, B., Zuchowski, M., Lei, W. K. J., Tscheak, P., Moencke-Buchner, E., Mueller, M. A., Krumbholz, A., Drexler, J. F., Drosten, C.
10.1101/2020.11.12.20230292 — Posted: 2020-11-13 Discussion: Onsite | Offsite
Age differential analysis of COVID-19 second wave in Europe reveals highest incidence among young adults
Aleta, A., Moreno, Y.
10.1101/2020.11.11.20230177 — Posted: 2020-11-13
SARS-CoV-2 IgG antibody responses in rt-PCR positive cases: first report from India
Dash, G. C., Parai, D., Choudhary, H. R., Peter, A., Rout, U. K., Nanda, R. R., Kanungo, S., Kshatri, J. S., Palo, S. K., Pati, S., Bhattacharya, D. D.
10.1101/2020.11.13.20229716 — Posted: 2020-11-13
Does the timing of government COVID-19 policy interventions matter? Policy analysis of an original database.
Stephens, M., Berengueres, J., Venkatapuram, S., Moonesar, I. A.
10.1101/2020.11.13.20194761 — Posted: 2020-11-13
An Early Assessment of Curfew and Second COVID-19 Lock-down on Virus Propagation in France
Baunez, C., Degoulet, M., Luchini, S., Pintus, P., Teschl, M.
10.1101/2020.11.11.20230243 — Posted: 2020-11-13

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).